Document Detail

Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study.
MedLine Citation:
PMID:  1810018     Owner:  NLM     Status:  MEDLINE    
In our present placebo-controlled study on recombinant tissue-type plasminogen activator (rt-PA) and heparin treatment of patients with acute ischaemic heart disease (IHD), we studied the extent of fibrin resolution and generation of coagulant activity. In rt-PA treated patients the lysis of fibrin in vivo (median 60 nmol of fibrin--estimated as fibrinogen equivalents) was significantly higher (p less than 0.02) than can be accounted for solely by lysis of a coronary thrombus (approximately 2 nmol) and circulating soluble fibrin (median 15 nmol). We observed a 200% increase of plasma concentrations of both prothrombin fragment 1 + 2 (p less than 0.001) and thrombin-antithrombin III complexes (p less than 0.001) as a consequence of rt-PA treatment, indicating that the coagulant activity is primarily caused by a physiological activation of the coagulation system. We conclude that an important contribution to the activation of coagulation in patients undergoing coronary thrombolysis is lysis of fibrin deposited widespread on the vascular intima, and that this process causes an intimal-dependent activation of the coagulation system.
S Munkvad; J Gram; J Jespersen
Related Documents :
1481188 - Oesophageal dissection after thrombolytic treatment for myocardial infarction.
12598798 - Pharmacoepidemiology and rheumatic diseases: 2001-2002.
6367408 - Intracoronary streptokinase in evolving acute myocardial infarction.
7612318 - Patient and doctor delay in acute myocardial infarction: a study in rotterdam, the neth...
11996628 - The prevention of sudden death in hypertrophic cardiomyopathy.
6883498 - Angiographic identification of primary coronary anomalies causing impaired myocardial p...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Scandinavian journal of clinical and laboratory investigation     Volume:  51     ISSN:  0036-5513     ISO Abbreviation:  Scand. J. Clin. Lab. Invest.     Publication Date:  1991 Nov 
Date Detail:
Created Date:  1992-05-27     Completed Date:  1992-05-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0404375     Medline TA:  Scand J Clin Lab Invest     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  581-90     Citation Subset:  IM    
Department of Clinical Chemistry, Ribe County Hospital, Esbjerg, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amino Acid Sequence
Blood Coagulation / physiology*
Coronary Disease / drug therapy*,  physiopathology
Coronary Vessels / physiopathology*
Double-Blind Method
Heparin / therapeutic use*
Middle Aged
Molecular Sequence Data
Recombinant Proteins / therapeutic use
Tissue Plasminogen Activator / therapeutic use*
Reg. No./Substance:
0/Recombinant Proteins; 9005-49-6/Heparin; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hepatitis B virus markers in alcoholics: clinical importance
Next Document:  Effects of short-term treatment with naproxen on kidney function in insulin-dependent diabetic patie...